Aridis Pharmaceuticals In... (ARDS)
0.00
-0.00 (-100.00%)
At close: Jan 14, 2025, 8:04 PM
undefined% (undefined)
| Bid | n/a |
| Market Cap | 4.46K |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.16 |
| PE Ratio (ttm) | 0 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | n/a |
| Volume | 600 |
| Avg. Volume (20D) | 17,468 |
| Open | 0.00 |
| Previous Close | 0.00 |
| Day's Range | 0.00 - 0.00 |
| 52-Week Range | 0.00 - 0.09 |
| Beta | undefined |
About ARDS
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-32...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 14, 2018
Employees 37
Stock Exchange NASDAQ
Ticker Symbol ARDS
Website https://www.aridispharma.com
Analyst Forecast
According to 1 analyst ratings, the average rating for ARDS stock is "Buy." The 12-month stock price forecast is $2, which is an increase of 1999900.00% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%